36results about How to "Improve steatosis" patented technology

The invention discloses a composition with an auxiliary protection effect on an alcoholic liver injury and a preparation method of the composition. The composition with the auxiliary protective effect on the alcoholic liver injury is mainly prepared from the following raw materials in parts by weight: 57.5-172.5 parts of kudzuvine root extract, 22.5-67.5 parts of semen hoveniae extract, 35-105 parts of salvia miltiorrhiza extract, 18-57 parts of turmeric extract and 7.5-22.5 parts of ammonium glycyrrhetate. The raw materials respectively have anti-lipid peroxidation effect and protective effect on the liver. Functional tests show that the composition with the auxiliary protection effect on the alcoholic liver injury has better liver protection effect compared with the same dose of single kudzuvine root extract preparation and single semen hoveniae extract preparation, and liver fatty degeneration and liver lipid peroxidation which are caused by the alcoholic liver injury can be obviously alleviated. The composition with the auxiliary protection effect is prepared by adopting a scientific and reasonable production process, is definite in functions, controllable in quality and safe to take and is applicable to a large group of people suffering from the alcoholic liver injury.

The invention discloses lactobacillus plantarum and application thereof in preparation of medicine or food for relieving diseases caused by hyperlipidemia, and belongs to the technical field of microorganism application. The lactobacillus plantarum is lactobacillus plantarum HH19058, and is preserved in the China Center for Type Culture Collection on December 24, 2020, the preservation number is CCTCC NO: M 2020966, and the address is located in Wuhan University, #299, Bayi Road, Wuchang District, Wuhan City, Hubei Province. The lactobacillus plantarum HH19058 is separated from pickled vegetables, has the effects of reducing the blood fat content of the human body and reducing the cardiovascular disease morbidity, and can be used for preparing the food and the medicine for relieving the hyperlipidemia.

The invention discloses a preservation number of CCTCC NO: M 2019595 Lactobacillus plantarumS58 and application thereof in preparation of products such as health care products, foods and medicines forrelieving obesity. The invention not only expands the application range of the Lactobacillus plantarumS58 and improves the utilization value of the Lactobacillus plantarumS58, but also brings new hope for treating obesity.

The invention discloses a semen hoveniae plant beverage and a preparation method thereof. The preparation method comprises the following steps: mixing 15g of semen hoveniae and 15g of pueraria lobata, and adding water as heavy as five times of the obtained mixture for soaking for 30 minutes; boiling by intense fire, and then keeping faint boiling by soft fire for decocting for 1 hour; filtering and collecting a first-time extracting solution; adding water as heavy as three times to obtain residues, and boiling by the intense fire; then keeping faint boiling by the soft fire for 1 hour, filtering and collecting a second-time extracting solution; merging the two extracting solutions, and concentrating to obtain a concentrated solution with a relative density of 1.05-1.1 at a temperature of 60 DEG C; adding the obtained concentrated solution and 0.002-0.006g of sucralose to a proper quantity of pure water, dissolving, and then puttingthe obtained mixture into a constant volume pot for obtaining a constant volume of 180ml by using pure water; uniformly stirring, and then heating for boiling; and filtering, hot encapsulating, sterilizing and packaging to obtain the semen hoveniae plant beverage. The semen hoveniae plant beverage has the effects of preventing the human bodies from being damaged after drinking and avoiding chemical liver injury caused by drinking too much; and the semen hoveniae plant beverage has the advantages of simple preparation process, no introduction of organic solvents, no organic solvent residue and easiness of production.

The invention belongs to the technical field of biological pharmacy, and discloses application of Piceatannol 3'-O-glucoside in preparation of a product for treating and/or preventing non-alcoholic fatty liver disease. Researches show that after the Piceatannol 3'-O-glucoside is continuously administrated to a non-alcoholic fatty liver disease (NAFLD) model mouse for four weeks, the contents of TC, TG and LDL in serum are remarkably reduced and the content of HDL is remarkably increased, which shows that the medicine has a lipid regulating effect; activity of AST and ALT in serum is remarkablyweakened and infiltration of inflammatory factors in liver tissue is relieved, which shows that the medicine has a liver protection effect; the fat content of the liver can be reduced and the pathological form of the fatty liver can be improved, which indicates that the medicine has an antagonistic effect on NASH. The test result shows that the Piceatannol 3'-O-glucoside has good development andapplication value in the aspect of preventing and treating the non-alcoholic fatty liver disease.

The invention discloses a Chinese herbal main component prescription for curing fatty liver, which contains the following the effective components based on the weight ratio: 0.01-50g of ginseng stem leaf saponin, 0.01-50g of panax notoginseng saponins and 0.01-50g of gastrodin. By adopting a conventional processing method, the component prescription can be manufactured into injectins, oral liquid, capsules or tablets. The Chinese herbal main component prescription has obvious effects for curing hyperlipidemia fatty liver and improving and culturing fatty degeneration of liver cells, looks for entry points for merging two different medical theory systems of Chinese and Western medicine, and has an important clinic application value for fatty liver prevention and cure; the research fruits can be used for developing modern Chinese herbal active ingredient products for curing the fatty liver, and lays a good foundation for developing modern prepared Chinese herb for curing the fatty liver with independent intellectual property rights; and the Chinese herbal main component prescription has small ingredients, easy separation and extraction, positive efficacy, good market prospect, and a certain practical significance for promoting the modernization of Chinese herb.

The invention discloses a drug for preventing and treating the alcoholic liver disease. Active ingredients of the drug comprise lactobacillus rhamnosus liquid supernatant and vitamin E, and preferablytanshinone IIA sodium sulfonate is added. Based on the modern pathological study, the drug is combined with the theory of traditional Chinese medicine; according to the curative effect, the drug hasthe effects of restoring intestinal barrier damages caused by alcohol, improving oxidization resistance of livers, improving cellular swelling and fatty degeneration of the livers, relieving fibrous septum, and the like, and has obvious prevention and treatment effect on acute alcoholic liver injury and alcohol hepatic fibrosis.

The invention discloses new application of a Chinese medicinal preparation, namely liver protecting tablets to the treatment of acute and chronic fatty liver. The liver protecting tablets consist of the following raw material medicaments by weight: 850 grams of stringy stonecrop herb, 500 grams of giant knotweed rhizome, 250 grams of root of red-rooted salvia and 200 grams of lucid ganoderma which are prepared into 1,000 tablets by the conventional method. The liver protecting tablets remarkably suppress the rise of hepatic tissue and serum lipid of a chronic fatty liver model, remarkably improve hepatic cell fatty degeneration and spotty necrosis, regulate fatty liver accompanying lipid metabolic disturbance well and delay and improve the occurrence and development of fatty liver. Therefore, a new clinical indication is realized for the liver protecting tablets.

The invention discloses a compound preparation with effective components of traditional Chinese medicine for treating non-alcoholic fatty liver diseases. The compound preparation is characterized in that the compound preparation comprises three effective components, namely, protopanoxadiol, tanshinone IIA and emodin, of the traditional Chinese medicine, and a molar ratio of protopanoxadiol to tanshinone IIA to emodin is (10-100) to (10-100) to (1-10). The compound preparation with the effective components of the traditional Chinese medicine can be prepared into clinically commonly used preparations such as tablets, granules, capsules or oral liquid according to conventional methods. The compound preparation with the effective components of the traditional Chinese medicine has the advantages that various medicines in different doses and proportions are compatible with one another by the aid of the weight formula methods and are screened by means of intervening liver cell fatty degeneration effects induced by fatty acid, accordingly, the liver cell fatty degeneration can be obviously improved, the lipid level of mice with non-alcoholic fatty livers can be lowered, and liver fat accumulation and liver cell injury of the mice can be relieved.

The invention discloses microcos paniculata total flavonoid glycosides (MpTFG) as well as a preparation method and application thereof. Flavonoid glycosides are 50% or above of the mass of the MpTFG,and comprises a flavone C-glycoside and a flavone O-glycoside, wherein the flavone C-glycoside is 30%-50% of the mass of the MpTFG; and the flavone O-glycoside is 10%-20% of the mass of the MpTFG. Experiments prove that the MpTFG disclosed by the invention can effectively improve the rat liver tissue fatty degeneration due to HFHF (high-fat high-fructose corn syrup) diet, and can remarkably alleviate the model rat metaflammation, and the obtained total flavonoid glycosides are sourced from medicinal and edible plants, are safe and reliable, have no toxic or side effects, and can be used as anactive component to be applied to preparation of a drug for preventing and controlling NAFLD (non-alcoholic fatty liver disease) or metaflammation induced by diet and a functional dietary supplement for enhancing liver glucolipid metabolism toughness.

The invention discloses a GLP-1R/GCGR/GIPR triple receptor agonist and application of the GLP-1R/GCGR/GIPR triple receptor agonist. The polypeptide compound provided by the invention has a parent peptide represented by the following amino acid sequence: H < X > a < 1 > < X > a < 2 > < Glu3-Gly4 < X > a < 5 >-Phe6 < X > a < 7 > < X > a < 8 >-Asp9 < Val < 10 > < X > a < 11 >-Ser12 < X > a < 13 > Leu14 < Glu15 < Gly16 < Gln < 17 >-X < aa < 18 >-Ala19 < X > a < 20 >-Glu21 < 1 >-Phe22 < Val < 27 >-X < aa < 18 >-Ala24 < Trp < 25 >-Leu26 < Val < 27 >-X < aa < 28 >-Gly29 < Arg < 30 >-Gly31 The polypeptide compound has the functions of reducing blood sugar, promoting insulin secretion, controlling appetite, regulating metabolic disorder, controlling lipolysis, improving heat consumption and the like, has the characteristics of good stability, high biological activity and the like, can be used as a GLP-1R/GCGR/GIPR triple receptor agonist, is expected to be used as a new-generation medicine for preventing or treating diabetes and obesity, and has wide application prospects. The traditional Chinese medicine composition can be used for preventing or treating diseases such as non-alcoholic fatty liver diseases, hyperlipidemia, arteriosclerosis and the like.

The invention discloses application of maca and moringa oleifera in treatment of alcoholic fatty liver disease, and belongs to the field of traditional Chinese medicine. The application proves that maca and moringa oleifera can intervene in the alcoholic fatty liver disease, can significantly reduce serum biochemical indexes such as ALT, TC and TG, and can improve liver fatty degeneration and lipid droplet reduction. The application expands a new direction for drug effect research of maca and moringa oleifera, and provides a new research drug for treatment and intervention of the alcoholic fatty liver disease.

The invention relates to application of a microbial metabolite in relieving glucose and lipid metabolism disorder, and particularly relates to application of AMP protein in preventing and/ or treatingobesity, fatty liver, diabetes and hyperlipidemia. By means of the application, the body weight gain and the blood fat content induced by high fat can be effectively reduced, the glucose tolerance isimproved, deposition of subcutaneous fat and visceral fat is reduced, liver damage and liver fatty degeneration are relieved, and the AMP protein has great significance in relieving obesity and fattyliver and is wide in application prospect.

The invention discloses a cactus polysaccharide composition, an antihypertensive drug and a health food, and belongs to the field of plant extracts. The cactus polysaccharide composition provided by the invention comprises cactus polysaccharide and a musaceae plant extracting solution, and can also comprise a cherry pit extract and/or an amaranth protein extract. Due to the fact that cactus polysaccharide can effectively control occurrence and development of hypertension, the cactus polysaccharide has good application value in treatment of hypertension under the condition that other plant extracts are reasonably added. The cactus composition provided by the invention consists of plant extracts, and is low in price and few in side effects.

The invention provides Bifidobacterium pseudocatenatum and application thereof in metabolic syndrome, and relates to the field of microorganisms. The preservation number of the Bifidobacterium pseudocatenatum is CGMCC No.22185, the Bifidobacterium pseudocatenatum is preserved in China General Microbiological Culture Collection Center on April 14, 2021, and the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No. 3, Beichen West Road, Chaoyang District, Beijing. According to the Bifidobacterium pseudocatenatum, the accumulation of liver cell lipid can be significantly inhibited, the body weight and the blood fat level can be reduced, the liver fatty degeneration can be further improved, and the important application significance can be provided for the alleviation of the occurrence of hyperlipidemia, obesity and fatty liver.

The invention relates to a prevention effect of rape pollen total flavonoids on non-alcoholic fatty liver induced by high fat. The method comprises the following steps: feeding a mouse with high fat for 10 weeks, establishing a non-alcoholic fatty liver mouse model, carrying out intragastric administration intervention while molding, carrying out intragastric administration intervention once a day, after 10 weeks, measuring AST and ALT levels in mouse serum, TG, TC, LDL-C and HDL-C contents and TG and TC content changes in liver tissues, and observing morphological changes of the liver tissues by an HE staining method. Compared with a model group, the rape pollen total flavonoids can significantly reduce the body weight of mice, reduce the levels of AST and ALT in serum, reduce the contents of TG, TC and LDL-C in serum, reduce the contents of TC and TG in liver tissues, increase the content of HDL-C in serum, and significantly improve the pathological morphology of the liver tissues of the mice. The rape pollen total flavonoids can prevent the non-alcoholic fatty liver induced by high fat by means of improving liver functions, regulating blood fat level, improving liver tissue lesions and the like.

The invention provides application of hyodeoxycholic acid to preparation of medicines for losing weight. After hyodeoxycholic acid is used for injecting high-fat feed-induced obese mice, the food intake of the mice is decreased by 30% compared with a control group, the body weights of the mice are decreased by 30% or above, and the fat weight and fat density of the mice are significantly reduced;therefore, hyodeoxycholic acid provided by the invention is proved to have a significant weight-loss effect and can be applied to the preparation of the weight-reducing medicines with a significant weight reducing effect. The invention also provides application of hyodeoxycholic acid in the preparation of medicines for treating or preventing obesity complications; the obesity complications are a series of diseases caused by metabolic disorders due to obesity.